Merck

September 26, 2017September 26, 2017

FDA Grants Accelerated Approval to Keytruda for Gastric Cancer

News

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Merck’s Keytruda (pembrolizumab) for the treatment of patients with advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. The ... Read more

September 15, 2017September 15, 2017

Updated Phase 3 Trial Results Continue to Favor Keytruda as Second-Line Treatment for Bladder Cancer

News

Patients with advanced urothelial cancer who received one prior line of chemotherapy live significantly longer when given Keytruda (pembrolizumab) as a second-line treatment instead of the standard of care ... Read more

September 12, 2017September 12, 2017

Keytruda Continues to Show Promise in Advanced Stomach Cancer Patients, Updated KEYNOTE-059 Data Show

News

Keytruda (pembrolizumab) is safe and has shown promising anti-tumor activity in patients with advanced gastric or gastroesophageal junction (GEJ) cancer, according to data presented at the European Society for Medical Oncology ... Read more

September 6, 2017September 6, 2017

Keytruda Approved in Europe for Certain Bladder Cancer Patients

News

The European Commission (EC) has approved Keytruda (pembrolizumab) for the treatment of certain patients with locally advanced or metastatic urothelial carcinoma, according to the therapy’s maker, Merck, known as MSD outside the ... Read more

July 21, 2017July 21, 2017

Opdivo, Yervoy, and Keytruda May Induce Rare Adverse Reactions Affecting the Eye, FDA Says

News

The U.S. Food and Drug Administration (FDA) is considering adding the risk of eye toxicities that could cause vision loss and retinal detachment on the labels of Bristol-Myers Squibb’s Opdivo ... Read more

July 14, 2017

PDS, Merck to Launch Trial Testing Combo Therapy in Treating Certain Head and Neck Cancer Patients

News

PDS Biotechnology Corporation and a subsidiary of Merck are collaborating to develop a Phase 2 clinical trial for a combination cancer treatment for people with certain types of head and ... Read more

June 14, 2017

Early Trial Data Supports Keytruda as Standalone Therapy for Advanced Stomach Cancers

News

Results from a first group of patients in a Phase 2 clinical trial appear to support Keytruda (pembrolizumab) being used to treat people with advanced or recurrent gastic or gastroesophageal junction adenocarcinoma ... Read more

May 25, 2017May 25, 2017

FDA Chalks Up a First by Approving Keytruda for Cancers with Specific Genetic Features

News

In a first, the U.S. Food and Drug Administration has approved a treatment for cancer patients with specific genetic features in their tumors rather than a specific tumor type. ... Read more

May 24, 2017

FDA Grants Priority Review to Keytruda for Heavily-treated Stomach Cancer Patients

News

The U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics Licence Application (sBLA) seeking approval for Keytruda (pembrolizumab) to treat patients with recurrent or advanced ... Read more

May 22, 2017

FDA Approves Keytruda as First- and Second-Line Therapy for Bladder Cancer

News

The U.S. Food and Drug Administration has approved Merck’s anti-PD1 therapy Keytruda (pembrolizumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma, or bladder cancer. Keytruda was granted ... Read more